To that effect, this review aims to examine and discuss the efficacy of the different animal and clinical studies conducted using a range of antidiabetic drugs such as metformin, insulin, incretins, dipeptidyl-peptidase 4 (DPP4) inhibitors, peroxisome proliferator-activated receptor γ (PPAR-γ) agonists, and sodium-glucose cotransporter 2 (SGLT2) in AD. Here, SLC5A2 is linked to Alzheimer disease.